OBJECTIVES: The mechanisms underlying the clinical benefits of mineralocorticoid receptor antagonism in patients with left ventricular (LV) dysfunction and heart failure (CHF) after myocardial infarction (MI) are poorly understood. METHODS: We investigated whether long-term (9 weeks) aldosterone antagonism with eplerenone (100 mg/kg/day) provides additional benefit to angiotensin II type 1 (AT1) receptor inhibition with irbesartan (50 mg/kg/day) on cardiac remodeling after MI in rats. RESULTS: Eplerenone monotherapy, like AT1 receptor blockade, significantly reduced LV end-diastolic pressure (LVEDP), end-systolic volume (LVESV) and end-diastolic volume (LVEDV) compared to placebo. Improvement of LV dilation by aldosterone antagonism was associated with a significant reduction of increased AT1 receptor, angiotensin-converting enzyme (ACE) and endothelin-1 gene expression in the noninfarcted LV myocardium. Combination therapy with irbesartan led to a substantial further leftward shift of the LV pressure-volume curve and decrease in LVEDP, LVESV and LVEDV. Moreover, combination therapy significantly improved LV systolic and diastolic function and reversed LV alterations of alpha- and beta-myosin heavy-chain isoforms, ANF and SERCA2 ATPase expression more effectively than monotherapies. LV collagen type I and type III expression as well as interstitial fibrosis were substantially increased in placebo CHF rats, similarly decreased by eplerenone and irbesartan, and further reduced by eplerenone/irbesartan. However, no additive effects of eplerenone/irbesartan on myocardial AT1 receptor, ACE and endothelin-1 mRNAs were observed. CONCLUSIONS: Aldosterone receptor antagonism provides additional benefit to AT1 receptor blockade on LV function and remodeling associated with improvement of molecular alterations responsible for progressive contractile dysfunction post-MI.
OBJECTIVES: The mechanisms underlying the clinical benefits of mineralocorticoid receptor antagonism in patients with left ventricular (LV) dysfunction and heart failure (CHF) after myocardial infarction (MI) are poorly understood. METHODS: We investigated whether long-term (9 weeks) aldosterone antagonism with eplerenone (100 mg/kg/day) provides additional benefit to angiotensin II type 1 (AT1) receptor inhibition with irbesartan (50 mg/kg/day) on cardiac remodeling after MI in rats. RESULTS:Eplerenone monotherapy, like AT1 receptor blockade, significantly reduced LV end-diastolic pressure (LVEDP), end-systolic volume (LVESV) and end-diastolic volume (LVEDV) compared to placebo. Improvement of LV dilation by aldosterone antagonism was associated with a significant reduction of increased AT1 receptor, angiotensin-converting enzyme (ACE) and endothelin-1 gene expression in the noninfarcted LV myocardium. Combination therapy with irbesartan led to a substantial further leftward shift of the LV pressure-volume curve and decrease in LVEDP, LVESV and LVEDV. Moreover, combination therapy significantly improved LV systolic and diastolic function and reversed LV alterations of alpha- and beta-myosin heavy-chain isoforms, ANF and SERCA2 ATPase expression more effectively than monotherapies. LV collagen type I and type III expression as well as interstitial fibrosis were substantially increased in placebo CHFrats, similarly decreased by eplerenone and irbesartan, and further reduced by eplerenone/irbesartan. However, no additive effects of eplerenone/irbesartan on myocardial AT1 receptor, ACE and endothelin-1 mRNAs were observed. CONCLUSIONS:Aldosterone receptor antagonism provides additional benefit to AT1 receptor blockade on LV function and remodeling associated with improvement of molecular alterations responsible for progressive contractile dysfunction post-MI.
Authors: Tiago Fernandes; Nara Y Hashimoto; Flávio C Magalhães; Fernanda B Fernandes; Dulce E Casarini; Adriana K Carmona; José E Krieger; M Ian Phillips; Edilamar M Oliveira Journal: Hypertension Date: 2011-06-27 Impact factor: 10.190
Authors: Danielle M Trappanese; Yuchuan Liu; Ryan C McCormick; Alessandro Cannavo; Gayani Nanayakkara; Marina M Baskharoun; Harish Jarrett; Felix J Woitek; D Michael Tillson; A Ray Dillon; Fabio A Recchia; Jean-Luc Balligand; Steven R Houser; Walter J Koch; Louis J Dell'Italia; Emily J Tsai Journal: Basic Res Cardiol Date: 2014-12-06 Impact factor: 17.165
Authors: Xiaohua Xu; Wenhan Wan; Anthony S Powers; Ji Li; Lisa L Ji; Shunhua Lao; Bryan Wilson; John M Erikson; John Q Zhang Journal: J Mol Cell Cardiol Date: 2007-10-12 Impact factor: 5.000
Authors: Adam Whaley-Connell; Javad Habibi; Nathan Rehmer; Sivakumar Ardhanari; Melvin R Hayden; Lakshmi Pulakat; Caroline Krueger; Carlos M Ferrario; Vincent G DeMarco; James R Sowers Journal: Metabolism Date: 2013-01-24 Impact factor: 8.694
Authors: Mengyun Lu; Li-Yuan Chen; Salina Gairhe; Adrien J Mazer; Stasia A Anderson; Jasmine N H Nelson; Audrey Noguchi; Mohammad Abdul Hai Siddique; Edward J Dougherty; Yvette Zou; Kathryn A Johnston; Zu-Xi Yu; Honghui Wang; Shuibang Wang; Junfeng Sun; Steven B Solomon; Rebecca R Vanderpool; Michael A Solomon; Robert L Danner; Jason M Elinoff Journal: Am J Physiol Lung Cell Mol Physiol Date: 2022-01-19 Impact factor: 5.464
Authors: Ivanita Stefanon; María Valero-Muñoz; Aurélia Araújo Fernandes; Rogério Faustino Ribeiro; Cristina Rodríguez; Maria Miana; José Martínez-González; Jessica S Spalenza; Vicente Lahera; Paula F Vassallo; Victoria Cachofeiro Journal: PLoS One Date: 2013-05-31 Impact factor: 3.240